Blueprint Medicines Corporation
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$69.6M
Doctors Paid
9,103
Transactions
29,163
2024 Total
$13.5M
Payment Breakdown by Category
Research$61.4M (88.1%)
Consulting$2.2M (3.2%)
Food & Beverage$683,912 (1.0%)
Travel$447,474 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $61.4M | 4,633 | 88.1% |
| Honoraria | $3.8M | 1,766 | 5.5% |
| Consulting Fee | $2.2M | 277 | 3.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 86 | 1.5% |
| Food and Beverage | $683,912 | 20,753 | 1.0% |
| Travel and Lodging | $447,474 | 1,498 | 0.6% |
| Grant | $27,500 | 2 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $27,054 | 12 | 0.0% |
| Education | $13,303 | 130 | 0.0% |
| Charitable Contribution | $808.50 | 5 | 0.0% |
| Gift | $300.00 | 1 | 0.0% |
Payments by Type
Research
$61.4M
4,633 transactions
General
$8.3M
24,530 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy | $13.8M | 1 | 1,166 |
| An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis | $6.2M | 0 | 546 |
| BLU-451-1101 | $5.5M | 0 | 271 |
| A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | $4.0M | 0 | 517 |
| BLU-667-1101 | $3.8M | 0 | 233 |
| BLU-945-1101 | $3.7M | 0 | 252 |
| A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | $2.6M | 0 | 258 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) | $2.1M | 0 | 211 |
| (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies | $1.9M | 0 | 147 |
| An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) | $1.4M | 0 | 193 |
| BLU-285-2101 | $1.3M | 0 | 130 |
| BLU-285-3101 | $1.1M | 0 | 127 |
| BLU-701-1101 | $991,446 | 0 | 107 |
| ESC-2021-002 | $980,577 | 0 | 2 |
| (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | $725,362 | 0 | 39 |
| BLU-285-1101 | $704,765 | 0 | 111 |
| Study Evaluating the Prevalence of the KIT D816V Mutation in Peripheral Blood of Patients With Evidence of Systemic Mast Cell Activation (MCA) | $385,090 | 1 | 77 |
| IST RFP.2021.001 | $359,617 | 0 | 2 |
| 2022-RFP-005: Mechanisms of Combinatorial Oncogenesis in Systemic Mastocytosis | $357,816 | 0 | 4 |
| IST-2020-002 | $323,344 | 0 | 3 |
| A Drug-drug Interaction Study of Avapritinib and Midazolam | $322,727 | 0 | 43 |
| 2022-RFP-002: Characterizing the cellular dynamics of KIT D816V mutated systemic mastocytosis on avapritinib and BLU-263 | $309,167 | 0 | 2 |
| Characterizing patient trajectories and reducing diagnos | $200,725 | 0 | 1 |
| IST-2020-001 | $195,038 | 0 | 1 |
| Ava + Aza Combo Trial | $187,645 | 0 | 3 |
| A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies | $180,467 | 0 | 26 |
| AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC | $173,170 | 0 | 19 |
| IST RFP.2021.001: Single-cell characterization of bone marrow in SM | $149,841 | 0 | 1 |
| An External Control, Observational, Retrospective Study Assessing the Effect of Avapritinib Compared with Best Available Therapy for Patients with Advanced Systemic Mastocytosis | $147,748 | 0 | 9 |
| BLU-285-0107 | $143,838 | 0 | 15 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. George Demetri, Md, MD | Medical Oncology | Boston, MA | $1.2M | $0 |
| Sandra Richman, M.d, M.D | Internal Medicine | Brookline, MA | $860,955 | $0 |
| Amro Elshoury, Md, MD | Internal Medicine | Indianapolis, IN | $206,641 | $0 |
| Dr. James Mccloskey, M.d, M.D | Hematology | Hackensack, NJ | $205,900 | $0 |
| Salman Fazal, M.d, M.D | Hematology & Oncology | Pittsburgh, PA | $193,500 | $0 |
| Dr. Anne Maitland, M.d, M.D | Allergy | Tarrytown, NY | $184,933 | $0 |
| George Yaghmour | Hematology & Oncology | Los Angeles, CA | $161,997 | $0 |
| Maeve O'connor, Md, MD | Allergy & Immunology | Charlotte, NC | $161,916 | $0 |
| Dr. Hana Safah, Md, MD | Hematology & Oncology | Baton Rouge, LA | $159,932 | $0 |
| Adrian Senderowicz, Md, MD | Medical Oncology | Bethesda, MD | $152,625 | $0 |
| Jeffrey Demain, M.d, M.D | Allergy & Immunology | Anchorage, AK | $148,941 | $0 |
| Marc Rudoltz, M.d, M.D | Radiation Oncology | West Orange, NJ | $129,675 | $0 |
| Dr. Lawrence Schwartz, M.d, M.D | Internal Medicine | Richmond, VA | $120,601 | $0 |
| Brian Hamilton, M.d, M.D | Pediatrics | Cambridge, MA | $114,100 | $0 |
| Brian Druker, Md, MD | Hematology & Oncology | Portland, OR | $104,727 | $0 |
| Charles Sawyers, M.d, M.D | Hematology & Oncology | New York, NY | $100,000 | $0 |
| Dr. Christopher Maisel, Md, MD | Hematology & Oncology | Dallas, TX | $99,527 | $0 |
| Dr. Andrew White, M.d, M.D | Allergy & Immunology | San Diego, CA | $97,394 | $0 |
| Sheeja Pullarkat, Md, MD | Anatomic Pathology | Los Angeles, CA | $92,871 | $0 |
| Dr. H Wedner, Md, MD | Allergy & Immunology | Saint Louis, MO | $75,280 | $0 |
| Dr. John Fahrenholz, M.d, M.D | Allergy & Immunology | Nashville, TN | $74,697 | $0 |
| Pankit Vachhani, Md, MD | Hematology & Oncology | Birmingham, AL | $73,165 | $0 |
| Dr. Diana Hausman, M.d, M.D | Specialist | Seattle, WA | $72,000 | $0 |
| Dr. Joshua Jacobs, Md, MD | Allergy & Immunology | Walnut Creek, CA | $67,694 | $0 |
| Dr. Tracy George, M.d, M.D | Hematology | Salt Lake City, UT | $66,120 | $0 |
About Blueprint Medicines Corporation
Blueprint Medicines Corporation has made $69.6M in payments to 9,103 healthcare providers, recorded across 29,163 transactions in the CMS Open Payments database. In 2024, the company paid $13.5M. The top product by payment volume is AYVAKIT ($3.2M).
Payments were distributed across 153 medical specialties. The top specialty by payment amount is Internal Medicine ($1.8M to 733 doctors).
Payment categories include: Food & Beverage ($683,912), Consulting ($2.2M), Research ($61.4M), Travel & Lodging ($447,474).
Blueprint Medicines Corporation is associated with 1 products in the CMS Open Payments database.